14 years of historical data (2012–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MediWound Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $152M | $210M | $177M | $92M | $67M | $64M | $101M | $84M | $110M | $104M | $100M |
| Enterprise Value | $156M | $214M | $175M | $86M | $34M | $55M | $85M | $79M | $103M | $68M | $71M |
| P/E Ratio → | -6.65 | — | — | — | — | — | — | 17.22 | — | — | — |
| P/S Ratio | 8.94 | 12.38 | 8.77 | 4.91 | 2.54 | 2.71 | 4.63 | 2.65 | 32.36 | 41.61 | 64.24 |
| P/B Ratio | 3.64 | 4.81 | 5.69 | 2.90 | 6.16 | — | 13.84 | 5.55 | 12.27 | 10.80 | 12.88 |
| P/FCF | — | — | — | — | — | — | — | 11.24 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 10.17 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.62 | 8.66 | 4.61 | 1.29 | 2.30 | 3.91 | 2.49 | 30.39 | 27.16 | 45.72 |
| EV / EBITDA | — | — | — | — | — | — | — | 14.01 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 26.42 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 10.54 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
MediWound Ltd. earns an operating margin of -149.1%. Operating margins have compressed from -83.0% to -149.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -63.9% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.2% | 19.2% | 13.0% | 19.1% | 49.7% | 36.9% | 34.7% | 62.7% | 38.6% | 36.8% | -38.5% |
| Operating Margin | -149.1% | -149.1% | -95.8% | -83.0% | -28.9% | -47.2% | -40.6% | 14.1% | -116.4% | -548.4% | -1293.6% |
| Net Profit Margin | -140.8% | -140.8% | -149.5% | -35.9% | -74.0% | -57.0% | -42.3% | 15.6% | -31.1% | -887.4% | -1212.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.9% | -63.9% | -96.3% | -31.6% | -619.0% | -1007.5% | -82.0% | 41.1% | -11.4% | -254.7% | -120.9% |
| ROA | -29.9% | -29.9% | -43.2% | -11.5% | -56.2% | -53.3% | -25.7% | 13.1% | -2.7% | -55.4% | -42.8% |
| ROIC | -49.5% | -49.5% | -52.9% | -589.5% | — | — | -844.6% | 55.3% | — | — | — |
| ROCE | -47.0% | -47.0% | -37.8% | -33.1% | -32.6% | -70.5% | -33.3% | 14.8% | -11.5% | -39.6% | -51.9% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($9M total debt minus $5M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.22 | 0.20 | 0.08 | — | 0.24 | 0.13 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.36 | — | — | — |
| Net Debt / Equity | — | 0.09 | -0.07 | -0.17 | -3.03 | — | -2.15 | -0.35 | -0.75 | -3.75 | -3.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -0.93 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -0.70 | — | — | — |
| Interest Coverage | -35.19 | -35.19 | -52.43 | -18.22 | -120.50 | -75.57 | -42.22 | 14.45 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
MediWound Ltd.'s current ratio of 2.33x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.59x to 2.33x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.33 | 2.33 | 1.97 | 4.59 | 3.80 | 1.39 | 3.17 | 3.43 | 6.68 | 7.64 | 6.25 |
| Quick Ratio | 2.17 | 2.17 | 1.86 | 4.33 | 3.64 | 1.28 | 3.00 | 3.28 | 6.34 | 7.30 | 6.09 |
| Cash Ratio | 2.07 | 2.07 | 1.63 | 3.84 | 2.81 | 1.03 | 2.59 | 2.82 | 4.83 | 6.64 | 5.58 |
| Asset Turnover | — | 0.20 | 0.28 | 0.28 | 0.53 | 1.20 | 0.70 | 0.78 | 0.10 | 0.06 | 0.04 |
| Inventory Turnover | 3.35 | 3.35 | 6.53 | 5.31 | 6.79 | 12.49 | 10.30 | 7.35 | 1.24 | 0.84 | 2.56 |
| Days Sales Outstanding | — | 51.05 | 105.63 | 86.32 | 133.56 | 34.82 | 47.63 | 49.77 | 780.01 | 502.46 | 641.68 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MediWound Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 5.8% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 8.9% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $10M | $9M | $5M | $4M | $4M | $4M | $4M | $3M | $3M |
Compare MDWD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $152M | -6.6 | — | — | 19.2% | -149.1% | -63.9% | -49.5% | — | |
| $872200 | -0.0 | -0.4 | — | — | — | -457.6% | — | 0.0 | |
| $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — | |
| $1B | -99.6 | — | 114.4 | 64.6% | -12.6% | -3.4% | -2.8% | — | |
| $351M | 4.8 | 1.1 | 3.3 | 99.4% | 28.9% | 19.9% | 167.9% | 0.2 | |
| $8B | 26.9 | 11.3 | 12.7 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 | |
| $297068 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — | |
| $127M | -894.1 | — | — | 29.6% | -18.0% | — | — | — | |
| $117B | 36.3 | 21.0 | 27.2 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 | |
| $66B | 22.9 | 20.4 | 18.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 | |
| $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDWD stock.
MediWound Ltd.'s current P/E ratio is -6.6x. The historical average is 17.2x.
MediWound Ltd.'s return on equity (ROE) is -63.9%. The historical average is -70.9%.
Based on historical data, MediWound Ltd. is trading at a P/E of -6.6x. Compare with industry peers and growth rates for a complete picture.
MediWound Ltd. has 19.2% gross margin and -149.1% operating margin.